Italian pharmaceutical company Recordati has reported a net profit
growth of 6.5 per cent to €18.5m in its third quarter results, as a
slump in sales was offset by lower costs.
Thermo Electron has continued to show strong growth in the third
quarter 2006 buoyed on by strong returns in its mass spectrometry
business and progress in its Triple Quad technology.
Fresh from Thermo's $10.4bn (€8.3bn) acquisition of the scientific
equipment and instrument specialists, Fisher Scientific posted
strong third quarter results that showed a profit rise of 62 per
cent coupled with an 11 per cent...
Two trade associations of the world's two largest pharma economies
- Europe and the US - took the unusual step of banding together at
the CPhI in Paris to condemn their regulatory authorities for poor
regulation of foreign active...
Portuguese drug producers are small and need to merge or form
alliances to compete at a global level, investing more in
innovation and increasing their competitiveness like custom
manufacturer Hovione has done, a new report by market...
Difficulties in identifying tablets have emerged as a major issue
in a recent US survey of 150 pharmacists who are warning drugmakers
that the lack of distinct appearance in pills leads in dispensing
errors that cost more than 7,000...
Europe's third party logistics providers (3PL) are evolving to
integrate more of their operations with those of their clients in a
bid to provide a more efficient service, leaving the old breed in
danger of becoming extinct.
Italian packaging and processing machinery company IMA Group has
posted a net profit of €13m for 2005, down 24 per cent from 2004,
since a rise in revenues was offset by one-off charges, operating
costs and a reduction in prices as...
According to a new report, the pharmaceutical market grew seven per
cent, to $602 billion (€501 billion) in 2005. The report
highlighted the emerging markets including China, Korea, Mexico,
Russia and Turkey, which experienced double-digit...
Increased sales and price hikes helped BASF achieve record earnings
in 2005, despite substantially higher raw material prices, Europe's
subdued economy and hurricanes in the US.
Quest Diagnostics, the US's leading provider of diagnostic testing,
information and services announced better than expected fourth
quarter results after increased clinical testing activity helped to
offset a weakness in its test...
French pharmaceutical company, Sanofi-Aventis, reported an increase
in sales for the fourth quarter with its vaccine business
continuing to impress. The company's performance precedes two
upcoming decisions later this year that...
Covance closed 2005 on a high after net revenues climbed 16.9 per
cent from 2004 to reach $1.19 bn (€1 bn). The current trend towards
outsourcing R&D, coupled with increased productivity and repeat
business has fuelled the company's...
Drug production company Patheon has released its fourth-quarter
results, which has revealed that profit has jumped 180 per cent
despite a recent production halt at a Puerto Rican subsidiary. This
bodes well for the recent manufacturing...
Filtration system Pall Corporation reported its first quarter
earnings which revealed earnings rose by 16 per cent, propelled by
growth in its industrial and biopharmaceuticals segments.
Chemical company Lanxess, release its third quarter results that
show restructuring strategy is bearing fruit, with sales up and the
reduction of net financial debt that is supported by strong growth
in the chemical industry.
The selection of pharma and biotech companies reporting results for
the third quarter of 2005 provided mixed indications as to the
state of the industry. Pipeline product fruition may be returning
among the industries as DrugResearcher.com...
Dutch pharmaceuticals and chemicals giant Akzo Nobel reported
third-quarter sales of €3,29 billion, a slight decrease from the
previous quarter but up 5.4 per cent from the comparable period in
2004, thanks to growth in all its units,...
The Hovione Group revealed its yearly figures for 2005, which
revealed that sales grew by 8 per cent. The company's performance
is in contrast to the pharma fine chemicals sector, which between
2002 and 2004 had an average 14...
Charles River Laboratories saw a double digit boost in fiscal
second quarter revenues with a leap in operating earnings, helped
by its acquisition of Inveresk Research Group, and also to
continuing strong demand for research models...
According to a recent survey, the pharma industry spent an
estimated $1.25 billion for each new molecular entity (NME)
approved by the FDA in 2004. The figure represents the second
consecutive year in which this figure has declined...
Dutch pharmaceuticals and chemicals giant Akzo Nobel reported
second-quarter sales of €3.34 billion, up 6 per cent from the
comparable period in 2004, thanks to price increases that overcame
flat volumes.
The world's biggest maker of birth-control pills, Schering AG, has
unveiled its second-quarter profit for 2005, which saw the
drugmaker's profits rise by 34 per cent, helped by sales of its
Yasmin contraceptive and gains...
Chemicals and pharmaceuticals firm Merck KGaA saw turnover rise but
pretax earnings dip in the second quarter of 2005, although the
results were skewed by the gain from its divestment of its
laboratory distribution business VWR International.
Indian pharmaceutical company Matrix Laboratories is aiming to buy
a 22 per cent controlling stake in Belgium's Docpharma in what is
the largest overseas acquisition yet in India's drug industry,
reports Phil Taylor.
According to a new report, the US pharmaceutical industry is
ignoring as much as $16 billion (€13 billion) in cash as the
industry struggles to cope with disappointing single-digit growth,
a lack of new products to replace drugs coming...
According to a new report by the National Academies, the advent of
increased global competition for outstanding students and
scientists has heightened the need for a widespread effort to
attract high calibre researchers to the US.
Germany's chemical companies have reported improved sales and
earnings in the first quarter of the year, and are optimistic of an
improved operating environment through 2005, reports Phil
Taylor.
Cardinal Health saw a double-digit hike in fiscal third quarter
revenues mirrored by a decline in operating earnings, as gains in
its drug distribution and medical products businesses were offset
by lower profits in sterile manufacturing...
Germany's Boehringer Ingelheim is claiming the number two spot
among the top 20 pharmaceutical companies for 2004 growth,
reporting double-digit gains for both revenues and operating
profit.
Danish analytical technology specialist Foss has reported a sharp
increase in organic growth in 2004, helped in part by the merger of
two of Foss subsidiaries, and the introduction of 10 new products
for the world market, reports...
The growth in the global pharmaceutical continued to slow in 2004,
with a 7 per cent hike to $550 billion, as the sector felt the
effects of increased pricing pressure and the expanding market for
lower-cost generic drugs, reports...
Italy's Recordati has reported flat turnover but a rise in
operating income in 2004, while its pharmaceutical chemicals
business managed to return to profit, reports Phil Taylor.
Pharmaceutical distribution and technology company Cardinal Health
reported a slide in profits in the second quarter of the year, as
an internal investigation into the company's accounting practices
claimed additional executive...
Hungary's Richter Gedeon reported rises in both overall sales and
profits in 2004, although its active pharmaceutical ingredient
(API) business remained under pressure in the US.
Akzo Nobel has reported a sharp rise in profits for 2004, but
warned that 2005 would be tough and that further divestments in its
chemicals portfolio are planned.
Cardinal Health reported its long-delayed fourth-quarter financial
results yesterday, revealing a hike in profit and revenues for the
three months to end June, but lowered guidance for the first half
of this fiscal year.
Finnish packaging giant Huhtamaki has reported flat sales figures
in the third quarter of 2004 due to adverse currency translations
and high raw material costs.
Germany's Bayer has reported a mixed set of results for the second
quarter with fine chemicals offshoot Lanxess contributing to an
unexpected 44 per cent hike in earnings before interest and tax
(EBIT).
Building on a stronger start to the year, Germany's third largest
chemicals group reports continued growth into the second quarter
with an increase in demand pushing up sales and earnings.
Despite Thermo Electron reporting a Q2 revenue growth of 12 per
cent, organic revenue growth declined from 5 per cent in 1Q04 to 3
per cent in the second quarter, due in part to the company's sale
of its Optical Technologies...
UK chemicals group Croda said strong demand for its marine and
plant-derived oils in the personal care and healthcare sectors
lifted sales and helped improve first half operating profits.
Dutch group DSM, one of Europe's top three ingredient suppliers to
drug makers, increased sales of pharma products during the second
quarter but continued losses from the antibiotics market halved the
Life Sciences operating...
Pressure on pharma ingredient supplier Lonza has continued into the
first half of the year, with consistently low use of custom
manufacturing capacity and weak demand for biomanufacturing
contributing to a 37 per cent drop in operating...
Dutch nucleic acid specialist Qiagen reported strong growth in
sales in the first quarter of 2004, ahead of its forecasts, as
spending by companies in the pharmaceutical industry returns to
historical levels, writes Wai Lang Chu.
Two leading central and eastern European pharma firms - both
producing both generic and branded drugs and active pharmaceuticals
- post results this week. Their results suggest CEE firms should
focus on foreign markets as pricing...
The raft of US laboratory equipment and consumables companies
reporting results for the first quarter of 2004 this week provides
convincing evidence that demand for these products has returned
among the pharmaceutical and biotechnology...
BASF and Merck KGaA have joined DSM in reporting encouraging
first-quarter 2004 results, raising hopes further that the European
chemicals sector may be about to move into recovery mode, writes
Phil Taylor.
The global market for nanocatalysts will amount to $3.7 billion in
2004 and is expected to reach $5.0 billion in 2009, according to
soon-to-be-released market research.